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Letter
Advanced cerebral amyloid 
angiopathy and small vessel 
disease are associated with 
psychosis in Alzheimer’s disease
IntroductIon
Psychotic symptoms may occur in any 
dementia, including Alzheimer’s disease 
(AD), but are particularly common in 
Lewy body dementia (LBD). The mecha-
nisms of psychotic symptoms are largely 
unknown. Psychosis has been found to 
be associated with more severe AD and 
Lewy body pathology in patients with AD 
and cerebrovascular disease-related vascu-
lopathy.1 One form of vascular pathology, 
cerebral amylod angiopathy (CAA), is 
defined as deposits of amyloid in the 
vessel walls that increase risk of haemor-
rhage and ischaemia. CAA contributes to 
neurodegeneration, but its relation to clin-
ical symptoms and course in dementia is 
not fully understood.2
The aim of this study was to investigate 
the postmortem pathological correlates of 
severe psychotic symptoms in moderate 
AD and LBD, which were followed annu-
ally from the time of diagnosis until death.
Methods
This is a 12-year prospective follow-up 
study of dementia ending in neuropatho-
logical examination. The 223 patients of 
the dementia study in Western Norway 
(Demvest) were diagnosed as mild 
dementia and followed annually with stan-
dardised clinical assessments until death. 
Patient were diagnosed according to stan-
dardised clinical criteria for AD3 and DLB4 
or PDD (both combined as LBD) and mild 
dementia defined as Mini Mental Status 
Examination (MMSE) score of at least 20 
or a Clinical Dementia Rating scale global 
score=1. The procedures are described 
in detail elsewhere.5 All comparisons are 
between groups are based on pathological 
defined diagnosis.
The validated Norwegian 12-item 
Neuropsychiatric Inventory (NPI) was 
used to assess neuropsychiatric symptoms. 
Presence of severe psychosis was based on 
the first 5 years after diagnosis and MMSE 
value above 10. NPI score of >4 on either 
item 1 (delusions) or 2 (hallucinations) 
was used as clinical significant cut-off.
Brain dissection, macroscopic descrip-
tion, regional sampling, tissue processing 
and staining were done following standard 
protocols including BrainNet Europe and 
Brains for Dementia Research UK. Cere-
bral amyloid angiopathy (none to mild as 
no, moderate to severe as yes) and small 
vessel disease (none to mild as no, moderate 
to severe as yes) were scored according to 
Vascular Cognitive Impairment Neuropa-
thology Guidelines and BrainNet Europe 
guidelines.6 7 The autopsy cohort did not 
differ significantly from the non-autopsy 
cohort for gender, education and baseline 
MMSE score but was slightly younger and 
had longer survival.8 Associations were 
tested using Fisher’s exact (binomial) and 
Mann-Whitney U tests (MW; continuous).
results
Of the first 50 cases autopsied, 31 were 
pathological diagnosed as AD and 16 as 
LBD. Four patients (two AD and two 
LBD) used antipsychotic drugs. Base-
line measurements and survival time are 
shown in table 1. Of note, AD patients 
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table 1  Baseline variables, survival time and pathology scores of early and severe psychosis in Alzheimer’s disease and Lewy body dementia
Alzheimer’s disease lewy body dementia
severe psychosis no psychosis severe psychosis no psychosis
(n=14) (n=17) (n=10) (n=6)
Gender, male/female, n 5/9 5/12 6/4 5/1
Age at baseline, years mean (SD) 75(8) 72(9) 74(9) 74(6)
Duration of disease, years mean (SD) 2.2 (2.5) 2.3 (1.7) 3.1 (2.1) 1.3 (1.0)
MMSE, score mean (SD) 23.9 (2.4) 25.3 (1.8) 24.1 (3.2) 24.7 (3.7)
NPI, total score mean (SD) 25 (23) 29 (27) 37 (22) 23 (17)
Survival time, mean (SD) 6.9 (1.4)* 8.4 (1.5) 4.7 (2.15) 4.3 (1.9)
Annual decline MMSE, mean (SD) 3.33 (1.44) 2.86 (1.21) 3.46 (2.02) 1.39 (3.31)
Hallucinations present, n 11 – 9 –
Delusions present, n 10 – 8 –
Neuropathology, n
  CERAD 0–B 0 2 6 4
C 14 15 4 2
  Braak tau stage 0–4 0 4 6 4
5–6 14 13 4 2
  Braak alpha-synuclein 0–4 11 12 1 0
5/6 3 5 9 6
  Cerebral amyloid angiopathy No 3 10 5 5
Yes 11* 7 5 1
  Small vessel disease No 3 11 5 2
Yes 11* 6 5 4
Baseline, survival and pathological scores of patients followed annually for up to 12 years with both Alzheimer’s disease and Levy body dementia defined by pathological 
diagnose.
*P<0,05 on Fisher’s exact (binomial) or Mann-Whitney U test.
†Patients with early and severe psychotic symptom identified as >4 score on NPI items 1 or 2 with MMSE >10.
‡Cerebral amyloid angiopathy and c small vessel disease was scored no (none and mild) or yes (moderate and severe) according to Vascular Cognitive Impairment 
Neuropathology Guidelines.
CERAD, Consortium to Establish a Registry for Alzheimer Disease neuritic plaques class; MMSE, Mini Mental State Examination; NPI, Neuropsychiatric Inventory.
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with psychosis had shorter survival than 
those without.
There were no significant associations 
between psychosis and amyloid plaques, 
tau or alpha-synuclein pathologies in the 
total group or in AD and LBD groups 
separately. Advanced SVD (p=0039) and 
CAA (p=0029) were more prominent in 
AD patients with psychosis, compared 
with AP patients without psychosis. There 
were no significant associations between 
vascular and neurodegenerative pathol-
ogies. There were no significant associ-
ations between either vascular or other 
pathologies and psychotic symptoms in 
patients with LBD.
CAA alone, but not SVD, showed 
significant associations with mean NPI 
item score of delusion (p=0028, MW) 
and hallucination (p=0031, MW) in 
AD. Patients with both CAA and SVD 
had higher item scores of delusions and 
hallucinations than those with one or 
none of the vascular pathologies. There 
were no significant associations between 
either vascular pathologies and annual 
cognitive decline or last observed MMSE 
in AD. Among the 41 patients with apoli-
poprotein E (ApoE) genotype available, 
no significant association to vascular 
pathology or psychosis was found.
To allow for comparison with other 
studies, associations between patho-
logical scores and psychotic symptoms 
present at the last observation or present 
ever during the study period were 
explored, but no significant associations 
were found.
dIscussIon
The main finding in this study was the 
association between advanced CAA and 
SVD with severe psychotic symptoms in 
moderate AD. To our knowledge, this is 
the first report on a potential link between 
CAA and psychotic symptoms in AD.
CAAs are amyloid (usually amyloid-
beta) deposits in vessel walls that constrict 
vascular lumen and may cause life- 
threatening lobar haemorrhages through 
weakening of the vessel wall. Some degree 
of CAA is often present in patients with 
AD. CAA can also contribute to neuro-
degeneration and cognitive dysfunc-
tion through microbleeds.2 Our sample 
had considerable comorbid vascular 
pathology, but all patients with AD 
fulfilled both clinical and pathological 
criteria of AD. There was no significant 
associations of vascular pathologies and 
severity of AD pathology.
Subcortical arteriosclerotic leukoen-
cephalopathy (SVD-related pathology) 
and vascular risk factors, but not specific 
vascular pathologies, were found associ-
ated with psychosis ever present.1 Vascular 
changes on MRI have also been associated 
with late onset schizophrenia, and there 
is an overlap between late onset schizo-
phrenia and early psychotic symptoms in 
dementia. Microvascular abnormalities 
are also found in schizophrenia, further 
supporting the vascular dysfunction 
element of psychosis.
Interestingly, the neuropsychological 
profile of both CAA and SVD in patients 
without clinical dementia is characterised 
by decreased processing speed, which 
is also found in psychotic diseases, and 
previous episode of psychosis is by far the 
strongest risk factor for development of 
psychosis in AD. Thus, vascular pathology 
and reduced information processing 
speed may be a risk factor of psychosis in 
dementia that are modifiable by cardiovas-
cular disease prevention.
Clinically misdiagnosed patients 
with dementia may be an important 
subgroup inflicting errors in trials and 
mixed AD with vascular dementia are often 
misdiagnosed as pure LDB.1 Our findings 
of vascular pathology and severe psychosis 
introduce a possible understanding of this 
subgroup and may improve diagnostic 
accuracy.
Causative conclusions about patho-
logical associations with early symptoms 
cannot be drawn from postmortem studies 
alone due to end-stage pathological data. 
Cerebrovascular pathologies take many 
years to develop and are associated with 
lifestyle and genetics risk factors. We 
found no association between vascular 
pathology and ApoE genotype. Epidemi-
ological and clinical studies show evidence 
for increased peripheral inflammatory 
markers in psychosis spectrum disorders,9 
and systemic inflammation is known to 
contribute to cerebrovascular patholo-
gies and cognitive impairment. There-
fore, inflammation may be a possible link 
between vascular pathology and psychosis 
in dementia. Long-term antipsychotic use, 
which may accelerate cerebrovascular 
disease, was low in our sample due restric-
tive national guidelines.
Strengths of the study include the 
prospective design with inclusion of 
patients from time of diagnosis, allowing 
us to identify those with early psychosis, 
and the selection of an unbiased cohort 
for autopsy, which did not differ from 
those without autopsy.8 Limitations of the 
study are the relatively small sample size 
with a risk of type II error, and there are 
no region-specific assessments of vascular 
pathologies.
In conclusion, severe psychosis in 
moderate AD is associated with advanced 
SVD and CAA postmortem. Accordingly, 
identifying and treating vascular disease 
and risk factors could reduce the emer-
gence of psychosis in patients with AD.
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